Efficacy and Safety of Duvelisib Following Disease Progression on Ofatumumab in Patients with Relapsed/Refractory CLL or SLL in the DUO Crossover Extension Study

Erstveröffentlichung
2020Authors
Davids, Matthew S.
Kuss, Bryone J.
Hillmen, Peter
Montillo, Marco
Moreno, Carol
Wissenschaftlicher Artikel
Published in
Clinical Cancer Research ; 26 (2020), 9. - S. 2096-2103. - ISSN 1078-0432. - eISSN 1557-3265
Link to publication
https://dx.doi.org/10.1158/1078-0432.CCR-19-3061Institutions
UKU. Klinik für Innere Medizin IIISubject headings
[Free subject headings]: CHRONIC LYMPHOCYTIC-LEUKEMIA | OPEN-LABEL | VENETOCLAX | INHIBITOR | IBRUTINIB[DDC subject group]: DDC 610 / Medicine & health